Share This Author
An Update on Current Therapeutic Drugs Treating COVID-19
It is hoped that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Patients receiving colchicine were approximately five times more likely to be discharged than those receiving standard of care at the end of the 28 day follow-up, and these observations warrant further investigation in large controlled clinical trials.
Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.
- L. Brunetti, Julie Kalabalik
- Medicine, BiologyP & T : a peer-reviewed journal for formulary…
- 1 December 2012
Treatment of hyperglycemia may involve glucose and non-glucose therapies, non-drug approaches, andnon-insulin agents.
Colchicine in COVID-19: an Old Drug, New Use
It is discussed how colchicine interferes with several inflammatory pathways, including inhibition of neutrophil chemotaxis, adhesion, and mobilization; disruption of superoxide production, inflammasome inhibition, and tumor necrosis factor reduction; and its possible antiviral properties.
The impact of abbreviations on patient safety.
Pharmacokinetics, Pharmacodynamics, and PKPD Modeling of Curcumin in Regulating Antioxidant and Epigenetic Gene Expression in Healthy Human Volunteers.
The results show that the bioavailability of the parent curcumin compound is low, and oral administration ofCurcumin can still deliver detectable levels of curCumin glucuronide metabolite, and antioxidant and epigenetic effects which could contribute to the overall health beneficial effects of Curcumin are elicited.
Prevalence of specific anti-skin autoantibodies in a cohort of patients with inherited epidermolysis bullosa
- M. Tampoia, D. Bonamonte, G. Annicchiarico
- Medicine, BiologyOrphanet Journal of Rare Diseases
- 4 September 2013
There is a higher prevalence of both anti-type VII collagen and other autoantibodies in patients with RDEB, but their presence can be interpreted as an epiphenomenon.
A FMEA clinical laboratory case study: how to make problems and improvements measurable.
- M. Capunzo, P. Cavallo, G. Boccia, L. Brunetti, S. Pizzuti
- MedicineClinical leadership & management review : the…
FMEA technique can be applied to the processes of a clinical laboratory, even if of small dimensions, and offers a high potential of improvement, but such activity needs a thorough planning because it is complex and even if the laboratory already operates an ISO 9000 Quality Management System.
Impact of tocilizumab administration on mortality in severe COVID-19
The current analysis does not support the use of tocilizumab for the management of cytokine storm in patients with COVID-19 and use of this therapeutic agent should be limited to the context of a clinical trial until more evidence is available.